Intervention Protocol

Steroid sparing drug treatments for polymyalgia rheumatica

  1. Samuel L Whittle1,
  2. Antonia Cole2,
  3. Sue Lester3,
  4. Catherine L Hill1,*

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD005325.pub2


How to Cite

Whittle SL, Cole A, Lester S, Hill CL. Steroid sparing drug treatments for polymyalgia rheumatica (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD005325. DOI: 10.1002/14651858.CD005325.pub2.

Author Information

  1. 1

    The Queen Elizabeth Hospital, Rheumatology Unit, Woodville, South Australia, Australia

  2. 2

    The Queen Elizabeth Hospital, Woodville, South Australia, Australia

  3. 3

    Hanson Institute, Arthritis Research Lab, Adelaide, South Australia, Australia

*Catherine L Hill, Rheumatology Unit, The Queen Elizabeth Hospital, 28 Woodville Rd, Woodville, South Australia, 5011, Australia. Catherine.Hill@nwahs.sa.gov.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main aim of this systematic review is to document the quality and quantity of available evidence on the use of glucocorticoid sparing medications in the treatment of PMR and thus provide a guide for practitioners. Specific objectives are:

  • To assess the effectiveness of glucocorticoid-sparing regimens.

This systematic review will also identify important questions for future research to address.